FY2025 EPS Estimates for Nyxoah Reduced by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised its FY2025 EPS estimates for Nyxoah to ($2.53), a decrease from the previous estimate of ($2.36).
• The company's recent quarterly earnings revealed a reported EPS of ($0.63), which missed the consensus estimate of ($0.62).
• In the second quarter, various institutional investors have increased their positions in Nyxoah, indicating growing interest in the company despite its financial challenges.

Nyxoah SA (NASDAQ:NYXH - Free Report) - Stock analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for Nyxoah in a research note issued to investors on Wednesday, August 20th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings of ($2.53) per share for the year, down from their prior estimate of ($2.36). The consensus estimate for Nyxoah's current full-year earnings is ($1.91) per share. Cantor Fitzgerald also issued estimates for Nyxoah's FY2026 earnings at ($1.61) EPS.

Nyxoah Price Performance

NYXH traded up $0.08 during midday trading on Friday, reaching $6.43. 79,931 shares of the company's stock were exchanged, compared to its average volume of 167,690. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.63 and a quick ratio of 2.38. The stock has a market capitalization of $219.01 million, a PE ratio of -2.80 and a beta of 1.61. The business's 50-day moving average price is $7.44 and its 200 day moving average price is $7.85. Nyxoah has a 1-year low of $5.55 and a 1-year high of $11.87.

Nyxoah (NASDAQ:NYXH - Get Free Report) last released its quarterly earnings data on Monday, August 18th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.01). The company had revenue of $1.58 million for the quarter, compared to analysts' expectations of $1.33 million. Nyxoah had a negative return on equity of 79.18% and a negative net margin of 1,541.84%.

Hedge Funds Weigh In On Nyxoah

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vestal Point Capital LP acquired a new position in Nyxoah during the fourth quarter worth about $23,394,000. Franklin Resources Inc. raised its position in Nyxoah by 0.9% during the second quarter. Franklin Resources Inc. now owns 294,990 shares of the company's stock worth $2,207,000 after acquiring an additional 2,655 shares during the last quarter. Kovack Advisors Inc. raised its position in Nyxoah by 148.2% during the second quarter. Kovack Advisors Inc. now owns 57,827 shares of the company's stock worth $433,000 after acquiring an additional 34,532 shares during the last quarter. Shay Capital LLC acquired a new position in Nyxoah during the second quarter worth about $374,000. Finally, Renaissance Technologies LLC acquired a new position in Nyxoah during the fourth quarter worth about $187,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.